country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P9981

Copy Link Print Information

Biologically Validated

Tafasitamab

Name: Tafasitamab
Brand: MedChemExpress
SKU: HY-P9981
Price: 290.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.71%
CAS. Nr.: 1422527-84-1
Molecular Weight:147.42 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Tafasitamab Chemical Structure

CAS. Nr.: 1422527-84-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Publications (2)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19^[1]^[2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

CD19

In Vitro

Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

NHL cell lines and primary CLL and MCL cells by γδ T cells
Concentration:
Incubation Time:

2 h
Result:

Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.

Cell Proliferation Assay^[2]

Cell Line:

SU-DHL-6 cells
Concentration:
Incubation Time:

72 h
Result:

Showed potent antiproliferative effects on tumor cell.

Apoptosis Analysis^[2]

Cell Line:

SU-DHL-6 cells
Concentration:

0-4 ng/mL
Incubation Time:

48 h
Result:

Showed potent antiproliferative effects due to caspase-induced apoptosis

In Vivo

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Disseminated Raji model^[1].
Dosage:

2.5 μg/kg
Administration:

Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:

Showed antitumor activity in disseminated Raji model.

Animal Model:

Disseminated Ramos model^[1].
Dosage:

10 mg/kg
Administration:

Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:

Showed antitumor activity in disseminated Ramos model.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

930 [NCBI]

Accession

P15391

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG1-G2-kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC₅₀ for this effect is 29.1 ng/mL.
Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 95.42 and 117.87 ng/mL.

Chemical Information

CAS. Nr. 1422527-84-1
Appearance Liquid
Molecular Weight 147.42 kDa
Color Colorless to light yellow
SMILES

[Tafasitamab]
Synonyms

XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All

Sort by:

Journal Impact Factor

Cytotherapy

2026 May 16.
Clin Chem Lab Med

Tafasitamab interference in immunofixation electrophoresis. [Abstract]

2025 Sep 15. PMID: 40965972

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (262 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [Content Brief]

[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Tafasitamab

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Biological Activity
Chemical Information
Publications (2)
Reinheit & Dokumentation
Verweise

1/16

IgG1-G2-kappa
1/16

Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC₅₀ for this effect is 29.1 ng/mL.
1/16

Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 95.42 and 117.87 ng/mL.
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tafasitamab

Inebilizumab

Rituximab

Obexelimab

Enoblituzumab

Blinatumomab

Human IgG1 kappa, Isotype Control

Enzalutamide

Adagrasib

Obinutuzumab (FUT8-KO)

Datopotamab deruxtecan (solution)

Polatuzumab vedotin

Sacituzumab govitecan

Publications Citing Use of MedChemExpress (MCE) Tafasitamab

Biologische Aktivität

Chemical Information

Publications (2)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bioz

Tafasitamab

Protein A Agarose

Bradford Protein Assay Kit

Cell-ATP Viability Detection Kit

HOLO Human Interleukin-2 (IL-2) Detection Kit

PBS Buffer (1×)

Cytotoxicity LDH Assay Kit

DPBS Buffer (1×)

Inebilizumab

Rituximab

Obexelimab

Enoblituzumab

Blinatumomab

Human IgG1 kappa, Isotype Control

Enzalutamide

Adagrasib

Obinutuzumab (FUT8-KO)

Datopotamab deruxtecan (solution)

Polatuzumab vedotin

Sacituzumab govitecan

Publications Citing Use of MedChemExpress (MCE) Tafasitamab

Biologische Aktivität

Chemical Information

Publications (2)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Tafasitamab Related Classifications

HY-P9981 Related Classifications

Bioz